Product search
Filter
Search results
BIOPHEN Factor VIII:C 6
Diagnosis of congenital or acquired FVIII deficiencies (hemophilia A). Follow-up of FVIII recovery in treated patients. Measurement of high FVIII concentrations.
BIOPHEN Factor VIII:C 2.5
Diagnosis of congenital or acquired FVIII deficiencies (hemophilia A). Follow-up of FVIII recovery in treated patients. Measurement of high FVIII concentrations.
BIOPHEN DTI (Direct Thrombin Inhibitors)
Assay proposed for the measurement of anti-IIa activity in research applications.
Tris buffer - progressive AT - Anti Xa, pH 7.85
Dilution buffer for progressive antithrombin activity assay, using a variant protocol for BIOPHEN®Antithrombin kit (ref. 221102/221105).
Tris buffer - progressive AT - Anti IIa, pH 8.40
Dilution buffer for progressive antithrombin activity using an anti IIa method, and a variant protocol of BIOPHEN®AT (Anti IIa) kit (ref. 221122), performed in the absence of heparin.
BIOPHEN Heparin anti-IIa (Kinetics)
Assay proposed for the measurement of heparin in research applications.
BIOPHEN Heparin (AT+)
Assay proposed for the measurement of heparin in research applications.
BIOPHEN Heparin 6
Measuring the heparin concentration in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN Heparin 3
Measuring the heparin concentration in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN DiXaI (Direct Xa Inhibitors)
Measurement of rivaroxaban and other factor Xa inhibitors in citrated plasma or other biological fluids. Note: BIOPHEN Heparin LRT and BIOPHEN Heparin (3 or 6) can also be used for testing direct factor Xa inhibitors (DiXaIs), such as rivaroxaban, apixaban or edoxaban. Adjusted protocols are available on demand.